loading
Aclaris Therapeutics Inc stock is traded at $3.11, with a volume of 16.13M. It is up +49.27% in the last 24 hours and up +157.14% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
See More
Previous Close:
$2.05
Open:
$2.43
24h Volume:
16.13M
Relative Volume:
20.58
Market Cap:
$202.86M
Revenue:
$31.25M
Net Income/Loss:
$-88.48M
P/E Ratio:
-2.0065
EPS:
-1.55
Net Cash Flow:
$-79.63M
1W Performance:
+16.35%
1M Performance:
+157.14%
6M Performance:
+157.14%
1Y Performance:
+220.65%
1-Day Range:
Value
$2.29
$3.19
1-Week Range:
Value
$2.03
$3.19
52-Week Range:
Value
$0.77
$3.19

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Name
Aclaris Therapeutics Inc
Name
Phone
484-324-7933
Name
Address
701 LEE ROAD, WAYNE, PA
Name
Employee
91
Name
Twitter
@aclaristx
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
ACRS's Discussions on Twitter

Compare ACRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ACRS 3.05 202.86M 31.25M -88.48M -79.63M -1.55
TMO 500.44 192.46B 42.37B 6.14B 7.78B 15.26
DHR 229.81 165.90B 23.74B 3.89B 4.98B 7.93
A 126.20 36.48B 6.50B 1.41B 1.42B 3.82
IDXX 421.38 34.55B 3.84B 866.24M 792.60M 9.80
IQV 190.51 34.31B 15.32B 1.41B 1.96B 5.95

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-14-22 Initiated Stifel Buy
Dec-01-22 Initiated Goldman Buy
Oct-06-22 Initiated BTIG Research Buy
Jul-23-21 Resumed Jefferies Buy
Jun-15-21 Initiated Piper Sandler Overweight
Apr-21-21 Initiated H.C. Wainwright Buy
Oct-22-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19 Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19 Initiated SVB Leerink Outperform
Mar-28-18 Resumed Leerink Partners Outperform
Feb-09-18 Initiated Guggenheim Buy
Jun-16-17 Initiated Cantor Fitzgerald Overweight
Nov-29-16 Initiated Leerink Partners Outperform
Sep-30-16 Initiated JMP Securities Mkt Outperform
Jun-10-16 Initiated Guggenheim Buy
Nov-02-15 Initiated Citigroup Buy
Nov-02-15 Initiated Jefferies Buy
View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

pulisher
09:57 AM

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

09:57 AM
pulisher
09:46 AM

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential - Digital More

09:46 AM
pulisher
09:08 AM

Aclaris secures $80 million in private stock sale - Investing.com

09:08 AM
pulisher
09:05 AM

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - The Manila Times

09:05 AM
pulisher
08:11 AM

Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewswire

08:11 AM
pulisher
08:11 AM

Aclaris Therapeutics Announces Exclusive, Global License - GlobeNewswire

08:11 AM
pulisher
Nov 15, 2024

Citadel Advisors LLC Adjusts Position in Aclaris Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at StockNews.com - MarketBeat

Nov 15, 2024
pulisher
Nov 13, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Position Boosted by BML Capital Management LLC - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week - Simply Wall St

Nov 12, 2024
pulisher
Nov 12, 2024

News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

Aclaris stock touches 52-week high at $2.68 amid market fluctuations By Investing.com - Investing.com South Africa

Nov 11, 2024
pulisher
Nov 11, 2024

Aclaris stock touches 52-week high at $2.68 amid market fluctuations - Investing.com

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 EPS Estimates for ACRS Reduced by Leerink Partnrs - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

Nov 09, 2024
pulisher
Nov 09, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by StockNews.com - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Aclaris Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo

Nov 08, 2024
pulisher
Nov 06, 2024

Aclaris Therapeutics Reports Positive Q3 2024 Milestones - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Aclaris: Q3 Earnings Snapshot - The Washington Post

Nov 06, 2024
pulisher
Nov 06, 2024

Aclaris Therapeutics Inc earnings missed by $0.10, revenue topped estimates - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire

Nov 06, 2024
pulisher
Oct 30, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat

Oct 26, 2024
pulisher
Oct 20, 2024

Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Oct 20, 2024
pulisher
Oct 09, 2024

Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Oct 08, 2024
pulisher
Oct 07, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat

Oct 07, 2024
pulisher
Oct 05, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat

Oct 05, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat

Oct 01, 2024
pulisher
Sep 23, 2024

Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily

Sep 23, 2024
pulisher
Sep 21, 2024

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN

Sep 21, 2024
pulisher
Sep 21, 2024

Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo

Sep 21, 2024
pulisher
Sep 18, 2024

AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch

Sep 18, 2024
pulisher
Sep 18, 2024

Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha

Sep 18, 2024
pulisher
Sep 18, 2024

Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena

Sep 18, 2024
pulisher
Sep 18, 2024

Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK

Sep 17, 2024
pulisher
Sep 17, 2024

Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Sep 17, 2024

Aclaris Therapeutics Inc Stock (ACRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aclaris Therapeutics Inc Stock (ACRS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Leonard Braden Michael
10% Owner
Aug 05 '24
Buy
1.24
206,025
256,357
14,250,000
Leonard Braden Michael
10% Owner
Aug 02 '24
Buy
1.29
167,544
216,400
14,043,975
Leonard Braden Michael
10% Owner
Jul 30 '24
Buy
1.30
173,730
226,370
13,776,421
Leonard Braden Michael
10% Owner
Jul 31 '24
Buy
1.33
100,000
132,640
13,876,421
Leonard Braden Michael
10% Owner
Jul 18 '24
Buy
1.30
130,317
169,555
13,578,286
Leonard Braden Michael
10% Owner
Jul 22 '24
Buy
1.33
17,716
23,557
13,602,691
Leonard Braden Michael
10% Owner
Jul 19 '24
Buy
1.30
6,689
8,696
13,584,975
Leonard Braden Michael
10% Owner
Jul 03 '24
Buy
1.16
143,288
166,071
13,324,952
Leonard Braden Michael
10% Owner
Jul 05 '24
Buy
1.15
123,017
141,334
13,447,969
Leonard Braden Michael
10% Owner
Jul 02 '24
Buy
1.14
86,092
98,489
13,181,664
$150.19
price up icon 2.78%
diagnostics_research LH
$238.78
price up icon 1.53%
diagnostics_research WAT
$353.45
price down icon 1.40%
$133.66
price down icon 1.05%
diagnostics_research MTD
$1,175.40
price down icon 0.49%
diagnostics_research IQV
$190.79
price down icon 1.07%
Cap:     |  Volume (24h):